New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
17:39 EDTABBVAbbVie declares inaugural dividend of 40c per share
The cash dividend is payable Feb. 15 to stockholders of record at the close of business on Jan. 15.
News For ABBV From The Last 14 Days
Check below for free stories on ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
11:15 EDTABBVRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
06:10 EDTABBVFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 15, 2014
10:55 EDTABBVRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
September 12, 2014
07:32 EDTABBVBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use